Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
News|Slideshows|August 4, 2016
Mortality and Medicine: 6 New Findings
Author(s)Leo Robert
A short slide show highlights results of 6 new clinical studies that look at death, risk of death, and cheating death.
Advertisement
Among the leading causes of death in the United States are heart disease, cancer, stroke (cerebrovascular diseases), Alzheimer disease, and diabetes, according to the CDC.Results of several recent clinical studies add to our understanding of mortality rates associated with various types of morbidity. Scroll through the slides above for key findings. For more information, see links to studies/abstracts below.
References:
Advertisement
Related to this article
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement